In a recent draft guidance, The National Institute for Health and Care Excellence has found Merck Sharpe & Dohme’s Remicade and Simponi, and AbbVie’s Humira to not be a cost effective treatment for ulcerative colitis. Final guidance on the use of the three drugs is expected in January 2015, will more information from the drug’s manufacturers lead to positive recommendations? Read more here. (Source: Kirstie Pickering, PMLiVE, 9/25/14).
You are here: / / Ulcerative Colitis Drug Trio Receives Negative Draft Guidance